Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Innate Pharma (IPHYF) Net Margin (2019 - 2025)

Historic Net Margin for Innate Pharma (IPHYF) over the last 7 years, with Q2 2025 value amounting to 807.14%.

  • Innate Pharma's Net Margin fell 5147300.0% to 807.14% in Q2 2025 from the same period last year, while for Jun 2025 it was 210.96%, marking a year-over-year decrease of 2106800.0%. This contributed to the annual value of 43.9% for FY2024, which is 402900.0% up from last year.
  • Latest data reveals that Innate Pharma reported Net Margin of 807.14% as of Q2 2025, which was down 5147300.0% from 430.44% recorded in Q4 2024.
  • Innate Pharma's 5-year Net Margin high stood at 1.61% for Q2 2023, and its period low was 947.58% during Q4 2021.
  • For the 5-year period, Innate Pharma's Net Margin averaged around 323.44%, with its median value being 201.73% (2023).
  • Per our database at Business Quant, Innate Pharma's Net Margin crashed by -5573600bps in 2021 and then skyrocketed by 9474700bps in 2022.
  • Over the past 5 years, Innate Pharma's Net Margin (Quarter) stood at 947.58% in 2021, then soared by 100bps to 0.11% in 2022, then plummeted by -101576bps to 111.05% in 2023, then tumbled by -288bps to 430.44% in 2024, then tumbled by -88bps to 807.14% in 2025.
  • Its Net Margin stands at 807.14% for Q2 2025, versus 430.44% for Q4 2024 and 292.4% for Q2 2024.